Pentokey Organy (India) Ltd Q3 FY26 – ₹24 Cr Market Cap, -₹0.46 EPS, 1,245 Working Capital Days & a Business Model That Survives on Interest Income
1. At a Glance – Blink and You’ll Miss It (But Your Capital Won’t)
Pentokey Organy (India) Ltd is a ₹24.4 crore market-cap microcap trading somewhere between “pharma distributor”, “chemical dealer”, and “interest-income enthusiast.” The stock is trading around ₹38.9, down ~15.7% in the last 3 months, while bravely flaunting a P/E of 62.6 on a business that just posted negative quarterly sales of ₹-2.09 crore and PAT of ₹-0.29 crore.
Yes, you read that right. Negative sales. That’s not a typo, that’s accounting.
ROE and ROCE are both sitting at 2.67%, which is basically fixed deposit returns minus the peace of mind. The company is debt-free (good), but also margin-free (bad), with OPM of just 1.54% on a full-year basis. Promoters hold 73%, pledges are zero, and dividends are… a myth.
This is one of those companies where the balance sheet looks cleaner than the income statement, and the cash flow tries its best to stay relevant. Curious already? Good. Because this story gets stranger.
2. Introduction – A Company That Refuses to Die (But Also Refuses to Grow)
Pentokey Organy was incorporated in 1986, which means it has survived liberalisation, multiple pharma booms, chemical cycles, demonetisation, GST, COVID, and several bull markets — yet somehow still operates at ₹4–5 crore annual revenue.
That’s not resilience. That’s stubbornness.
The company is officially in the business of trading pharmaceutical and chemical products, but unofficially, its interest income (9% of FY24 revenue) often plays a more consistent role than actual trading profits. When your P&L depends on “Other Income” to stay alive, you know the core business is on life support.
Quarterly results are wildly volatile. Some quarters show tiny profits, others slip into losses, and occasionally sales vanish entirely. And yet, the stock still trades at a valuation that assumes something magical might happen.
Will it? Or is this just a relic microcap floating on nostalgia and promoter control?
Let’s open the files.
3. Business Model – WTF Do They Even Do?
Pentokey Organy is a pure trading company. No fancy IP, no patented molecules, no complex chemistry — just buy chemicals, sell chemicals, collect money (eventually).
Product Portfolio (Yes, It’s a Long Grocery List)
Butyl Acetate
Ethyl Acetate
Acetaldehyde
Glacial Acetic Acid
Extra Neutral Alcohol
Hand Sanitizers
Sodium Dihydrogen Phosphate
Ethyl Phenyl Acetate
Cyanoacetyl Ethyl Urea …and a few more tongue-twisters.
These are commodity chemicals, widely available, price-sensitive, and brutally competitive. There is no pricing power, which explains the wafer-thin margins.
Manufacturing?
Technically, the company has a facility at MIDC Ratnagiri, but financially, this behaves far more like a trading desk than a manufacturer.
Revenue Mix (FY24)
Pharma product trading: ~91%
Interest income: ~9%
When nearly a tenth of revenue comes from interest, the business model deserves side-eye.
Geography
Domestic: 85%
Exports: 15%
Nothing exotic. No scale. No moat.
This is not a business that grows by innovation — it survives by not screwing up too badly.
4. Financials Overview – Numbers That Need Therapy
Result Type Lock
The latest announced results are clearly titled “Quarterly Results”. ➡️ EPS treatment locked as QUARTERLY RESULTS.
